<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02846181</url>
  </required_header>
  <id_info>
    <org_study_id>MO002A</org_study_id>
    <nct_id>NCT02846181</nct_id>
  </id_info>
  <brief_title>A Study to Assess the Mass Balance Recovery, Metabolite Profile and Metabolite Identification of [14C]-SK-1405</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanwa Kagaku Kenkyusho Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanwa Kagaku Kenkyusho Co., Ltd.</source>
  <brief_summary>
    <textblock>
      The primary objectives of the study are:&#xD;
&#xD;
        -  To assess the mass balance recovery after a single PO dose of [14C]-SK-1405&#xD;
&#xD;
        -  To provide plasma, urine and faecal samples for metabolite profiling and structural&#xD;
           identification&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2016</start_date>
  <completion_date type="Actual">August 2016</completion_date>
  <primary_completion_date type="Actual">August 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>14C radioactivity concentration excreted in urine</measure>
    <time_frame>Every day for 14 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>14C radioactivity concentration excreted in faeces</measure>
    <time_frame>Every day for 14 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>14C radioactivity concentration in whole blood</measure>
    <time_frame>Every day for 14 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>14C radioactivity concentration in plasma</measure>
    <time_frame>Every day for 14 days</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>Pruritus</condition>
  <arm_group>
    <arm_group_label>Healthy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>[14C]-SK-1405</intervention_name>
    <arm_group_label>Healthy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy males&#xD;
&#xD;
          -  Age 30 to 65 years of age&#xD;
&#xD;
          -  Body mass index of 18.0 to 30.0 kg/m2&#xD;
&#xD;
          -  Must be willing and able to communicate and participate in the whole study&#xD;
&#xD;
          -  Must provide written informed consent&#xD;
&#xD;
          -  Must have regular bowel movements (i.e. average stool production of ≥1 and ≤3 stools&#xD;
             per day)&#xD;
&#xD;
          -  Must agree to use an adequate method of contraception&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Participation in a clinical research study within the 3 months prior to IMP dose&#xD;
&#xD;
          -  Subjects who are study site employees, or immediate family members of a study site or&#xD;
             sponsor employee&#xD;
&#xD;
          -  Subjects who have previously been enrolled in this study&#xD;
&#xD;
          -  Subjects who have been dosed with SK-1405 in the past&#xD;
&#xD;
          -  Subjects who are taking, or have taken, antiepileptic and/or antidepressant medication&#xD;
             in the 6 months prior to dosing&#xD;
&#xD;
          -  Subjects who are taking, or have taken, any prescribed medication in the 28 days prior&#xD;
             to dosing, unless judged as not clinically significant by the investigator and sponsor&#xD;
&#xD;
          -  Subjects who are taking, or have taken, any over-the-counter medication (with the&#xD;
             exception of up to 2,000 mg/day paracetamol/acetaminophen) in the 7 days prior to&#xD;
             dosing, unless judged as not clinically significant by the investigator and sponsor&#xD;
&#xD;
          -  Use, during the 28 days prior to dosing, of any medicine or herbal remedy (such as St&#xD;
             John's wort) known to induce or inhibit CYP enzymes, unless judged as not clinically&#xD;
             significant by the investigator and sponsor&#xD;
&#xD;
          -  History of any drug or alcohol abuse in the past 2 years&#xD;
&#xD;
          -  History of clinically significant neurological conditions&#xD;
&#xD;
          -  A QTcF &gt;450 msec at screening, admission or pre-dose (as confirmed by a repeat ECG)&#xD;
&#xD;
          -  Regular alcohol consumption in males &gt;21 units per week (1 unit = ½ pint beer, 25 mL&#xD;
             of 40% spirit or a 125 mL glass of wine)&#xD;
&#xD;
          -  Current smokers and those who have smoked within the last 12 months; this includes&#xD;
             cigarettes, e-cigarettes and nicotine replacement products. A breath carbon monoxide&#xD;
             reading of greater than 10 ppm at screening or admission&#xD;
&#xD;
          -  Radiation exposure, including that from the present study, excluding background&#xD;
             radiation but including diagnostic x-rays and other medical exposures, exceeding 5 mSv&#xD;
             in the last 12 months or 10 mSv in the last 5 years. No occupationally exposed worker,&#xD;
             as defined in the Ionising Radiation Regulations 1999, shall participate in the study&#xD;
&#xD;
          -  Subjects who have been enrolled in an ADME study in the last 12 months&#xD;
&#xD;
          -  Subjects who do not have suitable veins for multiple venepunctures/cannulation as&#xD;
             assessed by the investigator at screening&#xD;
&#xD;
          -  Clinically significant abnormal biochemistry, haematology or urinalysis as judged by&#xD;
             the investigator, including AST, ALT or alkaline phosphatase &gt;1.5 × upper limit of&#xD;
             normal confirmed by repeat testing 18. Positive drugs of abuse test result&#xD;
&#xD;
          -  Positive hepatitis B surface antigen (HBsAg), hepatitis C virus antibody (HCV Ab) or&#xD;
             human immunodeficiency virus (HIV) results&#xD;
&#xD;
          -  Evidence of renal impairment at screening, as indicated by an estimated creatinine&#xD;
             clearance (CLcr) of &lt;90 mL/min using the Cockcroft-Gault equation&#xD;
&#xD;
          -  History of clinically significant psychiatric, cardiovascular, renal, hepatic, chronic&#xD;
             respiratory or gastrointestinal disease as judged by the investigator&#xD;
&#xD;
          -  History of gastrointestinal surgery (except appendectomy) or any condition that may&#xD;
             affect the absorption, distribution, metabolism or excretion of study drug in the&#xD;
             opinion of the investigator&#xD;
&#xD;
          -  Serious adverse reaction or serious hypersensitivity to any drug or the formulation&#xD;
             excipients&#xD;
&#xD;
          -  Presence or history of clinically significant allergy (including food or drug allergy)&#xD;
             requiring treatment, as judged by the investigator. Hayfever is allowed unless it is&#xD;
             active&#xD;
&#xD;
          -  Donation or loss of greater than 400 mL of blood within the 3 months prior to IMP dose&#xD;
&#xD;
          -  Subjects who have consumed St John's wort, red wine, Seville oranges, grapefruit or&#xD;
             grapefruit juice within 7 days prior to dosing. Subjects must be willing to refrain&#xD;
             from consuming such products until the last PK sample&#xD;
&#xD;
          -  Failure to satisfy the investigator of fitness to participate for any other reason&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Quotient Clinical Ltd.</name>
      <address>
        <city>Nottingham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>September 2016</verification_date>
  <study_first_submitted>July 11, 2016</study_first_submitted>
  <study_first_submitted_qc>July 24, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 27, 2016</study_first_posted>
  <last_update_submitted>November 21, 2016</last_update_submitted>
  <last_update_submitted_qc>November 21, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 23, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pruritus</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

